Bio-Rad laboratories have been under the spotlight given a mix of initiatives, expectations, and concerns surrounding the company. Recently, Bio-Rad put forth an offer to acquire Stilla Technologies, and has reportedly updated its Sartorius investment. However, these positive moves have been contrasted with a 4.2% downturn in shares, and quarterly earnings that missed expectations. Q4 revenue and guidance report also fell short causing the stock to drop by 4%. Though there have been various new investments in Bio-Rad Laboratories by firms such as Sivik Global Healthcare LLC, Lecap Asset Management Ltd., and DAVENPORT & Co LLC, its share price has experienced an overall slump. Exceptional increments in short interest have been noted, potentially signaling a bearish sentiment among investors. Earning estimates for Q4 have been boosted by analysts, however, Wells Fargo has lowered the company's stock price expectations. Although Bio-Rad has indicated an intention to buy digital PCR developer Stilla Technologies, doubts persist over a rumored $10 billion Qiagen acquisition.
Bio-Rad Laboratories Stocks News Analytics from Thu, 21 Jan 2021 08:00:00 GMT to Sat, 22 Feb 2025 07:47:18 GMT - Rating -3 - Innovation 2 - Information 7 - Rumor -1
